Principal Financial Group Inc. increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 0.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,751,479 shares of the company

RHL Group LLC cut its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 97.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 500 shares of the company

TD Asset Management Inc grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,334,726 shares of the company

Heritage Investors Management Corp lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 316,592 shares of the company

Advisors Management Group Inc. ADV redujo su participación en acciones de Merck & Co., Inc. (NYSE:MRK - Free Report) en un 95,0% en el segundo trimestre, según su presentación 13F más reciente ante la SEC. El fondo poseía 2.579 acciones de la empresa.

Wall Street Zen elevó las acciones de Merck & Co., Inc. de una calificación de "mantener" a una calificación de "comprar" en un informe de investigación del sábado.

Las acciones de Merck & Co. cotizan justo por debajo de un nuevo máximo histórico a finales de agosto de 2026 después de la fase 3 mela

Commonwealth Retirement Investments LLC cut its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 11.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,307 shares o

Acumen Wealth Advisors LLC reduced its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 70.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,919 shares of the company

El grupo Goldman Sachs aumentó su precio objetivo de Merck & Co., Inc. de 140,00 dólares a 160,00 dólares y otorgó a la empresa una calificación de "compra" en un informe del viernes.

TCW Group Inc. lessened its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 845,538 shares of the company

Summit Global Investments decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,039 shares of the company

Crew Capital Management Ltd increased its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 140.5% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,251 shares of the company

UBS Group elevó su precio objetivo de las acciones de Merck & Co., Inc. de 145,00 dólares a 175,00 dólares y otorgó a la compañía una calificación de "compra" en un informe del jueves.

Las acciones de Merck & Co. subieron en agosto de 2026 gracias a sólidos datos sobre vacunas contra el cáncer y nuevas actualizaciones de los analistas